a global pioneer in the research, cultivation, production and distribution of cannabis today celebrated the official opening of its European Union (EU) Campus located at Biocant Park
. Tilray CEO Brendan Kennedy, global senior leaders and the EU Campus Team welcomed guests from all over the world including international healthcare professionals, government officials and local dignitaries to celebrate the inauguration of the company’s European production and distribution centre.
For the event, which followed Tilray’s successful outdoor harvest last year and greenhouse harvest earlier this year, guests were invited to attend a ribbon-cutting ceremony and tour Tilray’s state-of-the-art facility.
Tilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals approximately 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs more than 100 professionals, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.
“We’re thrilled to celebrate another milestone as we continue to expand our global presence and pioneer the future of the cannabis industry. We are grateful for the warm welcome we’ve received from Portugal and the city of Cantanhede,” says Brendan Kennedy, Tilray CEO.
“We’re looking forward to utilizing Tilray’s EU Campus to serve the European Union medical cannabis markets with high-quality, pharmaceutical-grade medical cannabis products.”
Tilray announced a successful harvest from its EU Campus in February 2019 with multiple harvests expected in the coming months. Tilray looks forward to supplying patients in Europe from its EU Campus when it receives GMP certification.